NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 125)
Posted On: 01/07/2019 3:22:23 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Eagerly-Anticipated Commercial Launch of Biopharmaceuticals Contract Services Business
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences industry, this morning announced the commercial launch of its Biopharmaceuticals Contract Services Business. The eagerly-anticipated launch follows PBIO’s December 2017 acquisition of the assets of BaroFold, Inc., including patents, equipment, and other intellectual property relating to its unique, high pressure-based protein disaggregation and refolding platform. PBIO expects the technology platform to offer substantial improvement in the quality and costs of manufacturing protein therapeutics. “We are excited to announce the launch of our Biopharmaceutical Contract Services Business for the disaggregation and controlled refolding of proteins,” PBIO Chief Commercial Officer Dr. Bradford A. Young stated in the news release. “For companies involved in protein manufacturing, aggregation of proteins and challenges in achieving and maintaining optimal protein folding conformations are well-known issues that can dramatically reduce a drug’s efficacy and shelf-life. Our proprietary, pressure-based Barofold technology platform can help resolve and optimize these outcomes and can enable the development of novel protein therapeutics in both mammalian and non-mammalian systems, which we believe to be a very large and growing market opportunity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences industry, this morning announced the commercial launch of its Biopharmaceuticals Contract Services Business. The eagerly-anticipated launch follows PBIO’s December 2017 acquisition of the assets of BaroFold, Inc., including patents, equipment, and other intellectual property relating to its unique, high pressure-based protein disaggregation and refolding platform. PBIO expects the technology platform to offer substantial improvement in the quality and costs of manufacturing protein therapeutics. “We are excited to announce the launch of our Biopharmaceutical Contract Services Business for the disaggregation and controlled refolding of proteins,” PBIO Chief Commercial Officer Dr. Bradford A. Young stated in the news release. “For companies involved in protein manufacturing, aggregation of proteins and challenges in achieving and maintaining optimal protein folding conformations are well-known issues that can dramatically reduce a drug’s efficacy and shelf-life. Our proprietary, pressure-based Barofold technology platform can help resolve and optimize these outcomes and can enable the development of novel protein therapeutics in both mammalian and non-mammalian systems, which we believe to be a very large and growing market opportunity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)